Table 8.
The neighbors of candidate drug “camptothecin” on the validation network.
| Nodes | Description | Weight |
|---|---|---|
| TOP1 | Topoisomerase (DNA) I: the reaction catalyzed by topoisomerases leads to the conversion of one topological isomer of DNA to another. | 0.999 |
| CASP3 | Caspase 3: apoptosis-related cysteine peptidase: it is involved in the activation cascade of caspases responsible for apoptosis execution. | 0.965 |
| TP53 | Tumor protein p53: it acts as a tumor suppressor in many tumor types and induces growth arrest or apoptosis depending on the physiological circumstances and cell type. | 0.965 |
| Doxorubicin∗ | It is a drug used in cancer chemotherapy; it works by intercalating DNA, with the most serious adverse effect being life threatening heart damage. | 0.890 |
| ABCG2 | ATP-binding cassette, subfamily G (WHITE), member 2; xenobiotic transporter that may play an important role in the exclusion of xenobiotics from the brain. It may be involved in brain-to-blood efflux. It appears to play a major role in the multidrug resistance phenotype of several cancer cell lines. | 0.873 |
| CDK1 | Cyclin-dependent kinase 1: it plays a key role in the control of the eukaryotic cell cycle. It is required in higher cells for entry into S phase and mitosis. p34 is a component of the kinase complex that phosphorylates the repetitive C-terminus of RNA polymerase II. | 0.846 |
| ABCB1 | ATP-binding cassette, subfamily B (MDR/TAP), member 1; energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells. | 0.843 |
| BCL2 | B-cell CLL/lymphoma 2: it suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. It regulates cell death by controlling the mitochondrial membrane permeability. It appears to function in a feedback loop system with caspases. It inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1). | 0.820 |
| Paclitaxel∗ | It binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. | 0.812 |
| CDK2 | Cyclin-dependent kinase 2; involved in the control of the cell cycle; interacting with cyclins A, B1, B3, D, or E. Activity of CDK2 is maximal during S phase and G2. | 0.754 |
| Vinblastine∗ | An antimicrotubule drug used to treat certain kinds of cancer, including Hodgkin's lymphoma, non-small cell lung cancer, breast cancer, head and neck cancer, and testicular cancer. | 0.560 |
| Methotrexate∗ | It blocks the production of steroids derived from cholesterol and is clinically used in the treatment of Cushing's syndrome and metastatic breast cancer. | 0.554 |
| TOP2A | Topoisomerase (DNA) II alpha 170 kDa; control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. | 0.431 |
∗Known breast cancer drug.